{"id":"adequate-mood-stabilizer","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Weight gain"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4594585","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It achieves this by influencing the levels and activity of neurotransmitters such as serotonin and dopamine, which play a crucial role in regulating mood. This process helps to reduce the severity of mood swings and stabilize mood.","oneSentence":"This drug stabilizes mood by modulating neurotransmitter activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:44.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar disorder"},{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT06221852","phase":"NA","title":"Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder","status":"RECRUITING","sponsor":"Mclean Hospital","startDate":"2024-03-12","conditions":"Bipolar I Disorder, Psychosis, Schizoaffective Disorder","enrollment":50},{"nctId":"NCT06558201","phase":"NA","title":"Open Label Extension Study of NCT06221852","status":"ENROLLING_BY_INVITATION","sponsor":"Mclean Hospital","startDate":"2024-08-28","conditions":"Bipolar I Disorder, Schizoaffective Disorder, Psychosis","enrollment":50},{"nctId":"NCT00857584","phase":"PHASE3","title":"Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Bipolar Disorder, Bipolar Depression","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"adequate mood stabilizer","genericName":"adequate mood stabilizer","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug stabilizes mood by modulating neurotransmitter activity. Used for Bipolar disorder, Major depressive disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}